NewLink Genetics Scores Partnership With Merck For Experimental E
On Monday November 24th 2014 NewLink Genetics (NLNK) had announced that it had entered into a partnership agreement with Merck (MRK) to co-develop an experimental vaccine for Ebola known as rVSV-EBOV. Under the terms of the agreement Merck will pay an upfront payment to NewLink for $50 million dollars plus additional money from royalty on the Ebola candidate once…